These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19549264)

  • 1. Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn's disease.
    Kübler I; Koslowski MJ; Gersemann M; Fellermann K; Beisner J; Becker S; Rothfuss K; Herrlinger KR; Stange EF; Wehkamp J
    Aliment Pharmacol Ther; 2009 Sep; 30(6):621-33. PubMed ID: 19549264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease.
    Simms LA; Doecke JD; Walsh MD; Huang N; Fowler EV; Radford-Smith GL
    Gut; 2008 Jul; 57(7):903-10. PubMed ID: 18305068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease.
    Wehkamp J; Schmid M; Fellermann K; Stange EF
    J Leukoc Biol; 2005 Apr; 77(4):460-5. PubMed ID: 15618294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defensins and other antimicrobial peptides in inflammatory bowel disease.
    Wehkamp J; Schmid M; Stange EF
    Curr Opin Gastroenterol; 2007 Jul; 23(4):370-8. PubMed ID: 17545771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues.
    Wehkamp J; Chu H; Shen B; Feathers RW; Kays RJ; Lee SK; Bevins CL
    FEBS Lett; 2006 Oct; 580(22):5344-50. PubMed ID: 16989824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defensin-immunology in inflammatory bowel disease.
    Wehkamp J; Stange EF; Fellermann K
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S137-44. PubMed ID: 20117337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new look at Crohn's disease: breakdown of the mucosal antibacterial defense.
    Wehkamp J; Stange EF
    Ann N Y Acad Sci; 2006 Aug; 1072():321-31. PubMed ID: 17057212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defensins and inflammation: the role of defensins in inflammatory bowel disease.
    Ramasundara M; Leach ST; Lemberg DA; Day AS
    J Gastroenterol Hepatol; 2009 Feb; 24(2):202-8. PubMed ID: 19215333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial peptides are expressed and produced in healthy and inflamed human synovial membranes.
    Paulsen F; Pufe T; Conradi L; Varoga D; Tsokos M; Papendieck J; Petersen W
    J Pathol; 2002 Nov; 198(3):369-77. PubMed ID: 12375270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NOD2 and defensins: translating innate to adaptive immunity in Crohn's disease.
    Peyrin-Biroulet L; Chamaillard M
    J Endotoxin Res; 2007; 13(3):135-9. PubMed ID: 17621555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Follow up of Crohn's disease under therapy with hydro-MRI].
    Ganten M; Encke J; Flosdorff P; Grüber-Hoffmann B; Erb G; Hansmann J
    Radiologe; 2003 Jan; 43(1):26-33. PubMed ID: 12552372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug treatment of Crohn's disease].
    van Deventer SJ; Tytgat GN
    Ned Tijdschr Geneeskd; 1998 May; 142(21):1191-5. PubMed ID: 9627451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of chronic inflammatory bowel diseases].
    Lémann M
    Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concentrations of alpha- and beta-defensins in plasma of patients with inflammatory bowel disease.
    Yamaguchi N; Isomoto H; Mukae H; Ishimoto H; Ohnita K; Shikuwa S; Mizuta Y; Nakazato M; Kohno S
    Inflamm Res; 2009 Apr; 58(4):192-7. PubMed ID: 19184352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study.
    Chebli JM; Gaburri PD; De Souza AF; Pinto AL; Chebli LA; Felga GE; Forn CG; Pimentel CF
    J Gastroenterol Hepatol; 2007 Feb; 22(2):268-74. PubMed ID: 17295882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innate immune dysfunction in inflammatory bowel disease.
    Gersemann M; Wehkamp J; Stange EF
    J Intern Med; 2012 May; 271(5):421-8. PubMed ID: 22324936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment response and colonic gene expression in patients with Crohn's disease.
    Csillag C; Borup R; Olsen J; Nielsen FC; Nielsen OH
    Scand J Gastroenterol; 2007 Jul; 42(7):834-40. PubMed ID: 17558907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.
    Egan LJ; Sandborn WJ; Tremaine WJ
    Am J Gastroenterol; 1998 Mar; 93(3):442-8. PubMed ID: 9517654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of drug therapy for inflammatory bowel disease.
    Peppercorn MA
    Compr Ther; 1985 Dec; 11(12):14-9. PubMed ID: 2866866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Crohn's disease--a practical approach.
    Knutson D; Greenberg G; Cronau H
    Am Fam Physician; 2003 Aug; 68(4):707-14. PubMed ID: 12952387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.